Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Core Points - Medicus Pharma Ltd. held its annual and special meeting of shareholders on July 22, 2025, where all resolutions were passed [1] - The company elected all eight nominees for the board of directors, including Congresswoman Cathy McMorris Rodgers and Ajay Raju [2][3] - The shareholders expressed pride in electing a diverse and experienced leadership team in drug development and governance [2] Board Members - Congresswoman Cathy McMorris Rodgers has a distinguished record in public service, serving as a U.S. Representative for Washington's 5th Congressional District from 2004 to 2025 [4][5] - Ajay Raju is an attorney and venture capitalist with extensive experience in structured finance, real estate, and life sciences [8] - Dr. Raza Bokhari serves as Executive Chairman and CEO, with a background in life sciences and healthcare services [9][10] - Other continuing board members include Dr. Larry Kaiser, Robert J. Ciaruffoli, William L. Ashton, Barry Fishman, and Dr. Sara R. May, each bringing significant experience in their respective fields [13][14][15][16][17] Shareholder Approvals - Shareholders approved the appointment of KPMG LLP as auditors and authorized the board to fix the auditors' remuneration [18] - An amendment to the company's by-laws was approved to increase the quorum requirement for shareholder meetings [18] - Approval was granted for the issuance of common shares under the Standby Equity Purchase Agreement, which may exceed 20% of the outstanding shares [18] - An amendment to increase the voting threshold required to remove the Chairman of the Board to 75% was also approved [18] Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating clinical development programs for novel therapeutics [20] - The company is engaged in multiple countries across three continents [20] - SkinJect Inc., a subsidiary of Medicus, is developing a non-invasive treatment for basal cell skin cancer using a dissolvable microneedle patch [21] - The company announced a definitive agreement to acquire Antev, a UK-based biotech company, which is subject to certain closing conditions [22]